In case you have not seen it, FDA has produced a report based on the April 25th meeting. You can download it or read it here http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM368806.pdf. Based on the input received at the meeting and from material submitted to the docket, their characterization of ME is quite good. As a followup to the April FDA meeting, FDA is hosting a teleconference on Wednesday Oct 16th fro 1:30-3pm (eastern time). Details below. On October 16 from 1:30 PM – 3:00 PM EST, FDA will hold a teleconference that is open to the public. FDA will provide introductory and background remarks then the teleconference will be open for public comment on the following three topics: 1. Feedback from the CFS and ME public workshop. 2. Current projects related to drug development in CFS and ME. 3. Potential methods to catalyze CFS and ME drug development. Registration (Closes October 11, 2013): https://cfsmeteleconference2013.eventbrite.com/ FDA CFS and ME Activities Website: http://www.fda.gov/Drugs/NewsEvents/ucm319188.htm Please contact Randi Clark (Randi.Clark@fda.hhs.gov) or Mary Gross (Mary.Gross@fda.hhs.gov) if you have any questions.